Hospital Charge Master Pricing Drives Specialty Drug Costs

Specialty medications billed under medical benefits continue to pressure self-funded health plans. While utilization trends contribute to rising costs, hospital charge master pricing drives specialty drug costs more than many plan sponsors realize. These arbitrary starting points distort reimbursement long before a PPO discount is applied.

Golden Triangle Specialty Network recently conducted a focused review of billed charges and PPO-adjusted reimbursements across high-cost infusion therapies at two Indiana hospitals. The analysis was performed to better understand how pricing affects specialty reimbursement.

Where the Exposure Begins

Hospital charge master pricing established the baseline for outpatient drug reimbursement. PPO discounts are then applied to that baseline. When the starting point is inflated, the adjusted rate often remains well above defensible benchmarks.

Our review identified:

• Significant variation in billed charges for the same specialty medication
• Reimbursement levels that exceeded AWP-based standards, even after discounts
• Meaningful differences in cost depending on facility selection

These differences were not driven by clinical complexity. They were tied to hospital pricing methodology under medical benefits. A detailed summary of the methodology and aggregate financial impact is available here.

Why Percentage Discounts Do Not Solve the Structural Issue

Most network contracts apply a negotiated percentage discount to hospital charge master pricing. This model assumes the underlying billed charge is reasonable. When that assumption fails, the discount does not correct the imbalance.

As more infused biologics and specialty therapies migrate to outpatient settings, reliance on hospital charge master pricing introduces ongoing reimbursement variability across facilities and regions.

Establishing Structured Reimbursement Standards

Addressing this exposure requires a defined reimbursement methodology supported by enforceable plan authority.

Through GTRx Plus, GTSN works with plans to implement:

• Enforceable SPD language
• Mandatory preferred sourcing requirements
• Defined AWP-based reimbursement benchmarks
• Pre-service review before treatment initiation

This structure supports meaningful specialty pharmacy savings while maintaining appropriate member access and clinical oversight. Explore the GTRx Plus Strategy.

A More Disciplined Approach to Specialty Management

Specialty growth under medical benefits is expected to continue. Plans that evaluate how hospital charge master pricing influences reimbursement are better positioned to implement sustainable cost controls.

Golden Triangle Specialty Network partners with self-funded employers, TPAs, and advisors to reduce specialty drug exposure through structured, enforceable strategies aligned with long-term plan sustainability.